Raissy Hengameh H, Harkins Michelle, Esparham Anna, Kelly H William
School of Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico 87131, USA.
Pharmacotherapy. 2007 Sep;27(9):1231-6. doi: 10.1592/phco.27.9.1231.
To determine the effect of S-albuterol on the dose response to levalbuterol in patients with moderate bronchoconstriction induced by a methacholine challenge.
Prospective, randomized, double-blind, placebo-controlled, crossover study.
University-affiliated clinical trial center.
Twenty-two adults with mild, stable asthma.
At the screening visit, patients were switched from their beta2-agonist to ipratropium bromide for use as an as-needed rescue therapy. At the baseline visit 2-6 days later, the provocative concentration of methacholine to induce a 30% decrease in forced expiratory volume in 1 second (FEV(1) PC(30)) was determined, followed by a nebulized racemic albuterol dose-response study with three doses of albuterol, to familiarize patients with the procedures. At visits 2 and 3, patients were randomly assigned to receive nebulized normal saline placebo or S-albuterol 5 mg before the methacholine challenge and were administered three escalating doses of levalbuterol after the challenge.
Area under the curve for FEV(1) over 40 minutes (AUC(0-40)) after administration of levalbuterol was the primary outcome, with slope of FEV(1) as the secondary outcome. In addition, the fraction of exhaled nitric oxide (FeNO) was measured before and after the challenges. In the 17 patients who met criteria for completion, no deleterious effect for S-albuterol was found for FEV(1) PC(30), AUC(0-40) FEV(1), or the FEV(1) slope(0-40). However, S-albuterol reduced the provocative concentration of methacholine to induce a 20% decrease in FEV(1) (PC(20) 0.52 +/- 2.06 vs 0.39 +/- 1.58 mg/ml, placebo vs S-albuterol, p=0.044) but did not affect FeNO.
A single high dose of S-albuterol did not alter the bronchodilator response to levalbuterol. The effect on bronchial responsiveness requires further study.
确定S-沙丁胺醇对乙酰甲胆碱激发试验诱导的中度支气管收缩患者中左旋沙丁胺醇剂量反应的影响。
前瞻性、随机、双盲、安慰剂对照、交叉研究。
大学附属临床试验中心。
22名轻度、稳定哮喘成年患者。
在筛查访视时,患者停用其β2激动剂,改用异丙托溴铵作为按需急救治疗药物。在2 - 6天后的基线访视时,确定诱导第1秒用力呼气量(FEV(1))下降30%的乙酰甲胆碱激发浓度(FEV(1) PC(30)),随后进行雾化消旋沙丁胺醇剂量反应研究,给予三剂沙丁胺醇,以使患者熟悉操作流程。在第2次和第3次访视时,患者在乙酰甲胆碱激发试验前被随机分配接受雾化生理盐水安慰剂或5毫克S-沙丁胺醇,并在激发试验后给予三剂递增剂量的左旋沙丁胺醇。
左旋沙丁胺醇给药后40分钟内FEV(1)的曲线下面积(AUC(0 - 40))为主要结局指标,FEV(1)斜率为次要结局指标。此外,在激发试验前后测量呼出一氧化氮分数(FeNO)。在符合完成标准的17名患者中,未发现S-沙丁胺醇对FEV(1) PC(30)、AUC(0 - 40) FEV(1)或FEV(1)斜率(0 - 40)有不良影响。然而,S-沙丁胺醇降低了诱导FEV(1)下降20%的乙酰甲胆碱激发浓度(PC(20) 0.52±2.06对0.39±1.58毫克/毫升,安慰剂对S-沙丁胺醇,p = 0.044),但不影响FeNO。
单次高剂量S-沙丁胺醇未改变对左旋沙丁胺醇的支气管舒张反应。其对支气管反应性影响有待进一步研究。